Which has higher earnings & valuation, DMAC or ORIC?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is DMAC or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Oric Pharmaceuticals N/A -35.35% -33.39%

Does the media refer more to DMAC or ORIC?

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 2 mentions for DiaMedica Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.95 beat DiaMedica Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, OMER or DMAC?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros N/A N/A -$3.35M $1.28 14.93 DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A

Is OMER or DMAC more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% DiaMedica Therapeutics N/A -77.76% -69.43%

Does the media prefer OMER or DMAC?

In the previous week, Omeros had 13 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 15 mentions for Omeros and 2 mentions for DiaMedica Therapeutics. Omeros' average media sentiment score of 0.69 beat DiaMedica Therapeutics' score of 0.00 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, VOR or DMAC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A

Is VOR or DMAC more profitable?

Vor Biopharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A DiaMedica Therapeutics N/A -77.76% -69.43%

Does the media prefer VOR or DMAC?

In the previous week, Vor Biopharma had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Vor Biopharma and 2 mentions for DiaMedica Therapeutics. Vor Biopharma's average media sentiment score of 0.93 beat DiaMedica Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DMAC or MGTX?

In the previous week, MeiraGTx had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for DiaMedica Therapeutics. MeiraGTx's average media sentiment score of 1.41 beat DiaMedica Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, DMAC or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A Jade Biosciences N/A N/A -$127.41M -$1.92 N/A

Is DMAC or JBIO more profitable?

Jade Biosciences' return on equity of -49.11% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Jade Biosciences N/A -49.11% -45.62%

Does the media refer more to DMAC or JBIO?

In the previous week, Jade Biosciences had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Jade Biosciences and 2 mentions for DiaMedica Therapeutics. Jade Biosciences' average media sentiment score of 0.72 beat DiaMedica Therapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jade Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DiaMedica Therapeutics (DMAC) Competitors

$6.56 -0.19 (-2.81%)

As of 04:00 PM Eastern

Compare

DMAC vs. ORIC, OMER, VOR, MGTX, and JBIO

Should you buy DiaMedica Therapeutics stock or one of its competitors? DiaMedica Therapeutics's main competitors and comparable companies include Oric Pharmaceuticals (ORIC), Omeros (OMER), Vor Biopharma (VOR), MeiraGTx (MGTX), and Jade Biosciences (JBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does DiaMedica Therapeutics compare to Oric Pharmaceuticals?

DiaMedica Therapeutics (NASDAQ:DMAC) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Oric Pharmaceuticals had 5 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 2 mentions for DiaMedica Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.95 beat DiaMedica Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

Oric Pharmaceuticals' return on equity of -35.35% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

DiaMedica Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 82.93%. Oric Pharmaceuticals has a consensus target price of $19.45, suggesting a potential upside of 52.70%. Given DiaMedica Therapeutics' higher possible upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Oric Pharmaceuticals beats DiaMedica Therapeutics on 9 of the 13 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

48.8% of Omeros shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Omeros currently has a consensus target price of $38.00, indicating a potential upside of 98.85%. DiaMedica Therapeutics has a consensus target price of $12.00, indicating a potential upside of 82.93%. Given Omeros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Omeros is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Omeros has a beta of 2.6, meaning that its share price is 160% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, Omeros had 13 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 15 mentions for Omeros and 2 mentions for DiaMedica Therapeutics. Omeros' average media sentiment score of 0.69 beat DiaMedica Therapeutics' score of 0.00 indicating that Omeros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	14.93
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

DiaMedica Therapeutics' return on equity of -77.76% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

Summary

Omeros beats DiaMedica Therapeutics on 12 of the 14 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vor Biopharma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Vor Biopharma presently has a consensus price target of $43.38, indicating a potential upside of 78.94%. DiaMedica Therapeutics has a consensus price target of $12.00, indicating a potential upside of 82.93%. Given DiaMedica Therapeutics' higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Vor Biopharma had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 6 mentions for Vor Biopharma and 2 mentions for DiaMedica Therapeutics. Vor Biopharma's average media sentiment score of 0.93 beat DiaMedica Therapeutics' score of 0.00 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vor Biopharma's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Summary

Vor Biopharma beats DiaMedica Therapeutics on 9 of the 11 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to MeiraGTx?

DiaMedica Therapeutics (NASDAQ:DMAC) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

DiaMedica Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 5.0% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

DiaMedica Therapeutics has higher earnings, but lower revenue than MeiraGTx. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
MeiraGTx	$81.39M	16.48	-$114.20M	$0.71	19.68

In the previous week, MeiraGTx had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for MeiraGTx and 2 mentions for DiaMedica Therapeutics. MeiraGTx's average media sentiment score of 1.41 beat DiaMedica Therapeutics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 82.93%. MeiraGTx has a consensus target price of $26.17, suggesting a potential upside of 87.31%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

MeiraGTx has a net margin of 19.87% compared to DiaMedica Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
MeiraGTx	19.87%	283.85%	29.39%

Summary

MeiraGTx beats DiaMedica Therapeutics on 15 of the 16 factors compared between the two stocks.

How does DiaMedica Therapeutics compare to Jade Biosciences?

DiaMedica Therapeutics (NASDAQ:DMAC) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Jade Biosciences is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

DiaMedica Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 82.93%. Jade Biosciences has a consensus price target of $51.75, suggesting a potential upside of 160.71%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Jade Biosciences is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences' return on equity of -49.11% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Jade Biosciences	N/A	-49.11%	-45.62%

DiaMedica Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, Jade Biosciences had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Jade Biosciences and 2 mentions for DiaMedica Therapeutics. Jade Biosciences' average media sentiment score of 0.72 beat DiaMedica Therapeutics' score of 0.00 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jade Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jade Biosciences beats DiaMedica Therapeutics on 10 of the 14 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAC vs. The Competition

Export

Metric	DiaMedica Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$364M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-9.11	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	9.24	16.29	12.89	6.14
Net Income	-$32.77M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.81%	-1.37%	-0.33%	-1.47%
1 Month Performance	0.61%	11.07%	6.51%	2.47%
1 Year Performance	23.77%	53.71%	25.19%	15.84%

DiaMedica Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAC DiaMedica Therapeutics	1.2918 of 5 stars	$6.56 -2.8%	$12.00 +82.9%	+26.9%	$364M	N/A	N/A	20
ORIC Oric Pharmaceuticals	3.0644 of 5 stars	$13.24 -3.6%	$19.45 +46.9%	+26.5%	$1.37B	N/A	N/A	80	Positive News
OMER Omeros	4.0554 of 5 stars	$18.61 -3.3%	$38.00 +104.2%	+339.6%	$1.35B	$38.42M	14.54	210	Insider Trade
VOR Vor Biopharma	2.3771 of 5 stars	$22.65 -3.7%	$43.38 +91.5%	-39.3%	$1.34B	N/A	N/A	140	News Coverage
MGTX MeiraGTx	4.132 of 5 stars	$13.82 -2.3%	$26.17 +89.3%	+92.6%	$1.33B	$397.50M	19.46	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAC) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. ORIC, OMER, VOR, MGTX, and JBIO

How does DiaMedica Therapeutics compare to Oric Pharmaceuticals?

Summary

How does DiaMedica Therapeutics compare to Omeros?

Summary

How does DiaMedica Therapeutics compare to Vor Biopharma?

Summary

How does DiaMedica Therapeutics compare to MeiraGTx?

Summary

How does DiaMedica Therapeutics compare to Jade Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DiaMedica Therapeutics (DMAC) Competitors

DMAC vs. ORIC, OMER, VOR, MGTX, and JBIO

How does DiaMedica Therapeutics compare to Oric Pharmaceuticals?

Does the media refer more to DMAC or ORIC?

Which has higher earnings & valuation, DMAC or ORIC?

Is DMAC or ORIC more profitable?

Which has more volatility & risk, DMAC or ORIC?

Do analysts rate DMAC or ORIC?

Do insiders and institutionals have more ownership in DMAC or ORIC?

Summary

How does DiaMedica Therapeutics compare to Omeros?

Do insiders & institutionals believe in OMER or DMAC?

Do analysts prefer OMER or DMAC?

Which has more volatility & risk, OMER or DMAC?

Does the media prefer OMER or DMAC?

Which has better earnings and valuation, OMER or DMAC?

Is OMER or DMAC more profitable?

Summary

How does DiaMedica Therapeutics compare to Vor Biopharma?

Do insiders and institutionals believe in VOR or DMAC?

Which has more volatility & risk, VOR or DMAC?

Do analysts recommend VOR or DMAC?

Does the media prefer VOR or DMAC?

Is VOR or DMAC more profitable?

Which has better valuation & earnings, VOR or DMAC?

Summary

How does DiaMedica Therapeutics compare to MeiraGTx?

Which has more risk & volatility, DMAC or MGTX?

Do insiders & institutionals believe in DMAC or MGTX?

Which has better earnings & valuation, DMAC or MGTX?

Does the media refer more to DMAC or MGTX?

Do analysts prefer DMAC or MGTX?

Is DMAC or MGTX more profitable?

Summary

How does DiaMedica Therapeutics compare to Jade Biosciences?

Do insiders and institutionals hold more shares of DMAC or JBIO?

Which has higher earnings and valuation, DMAC or JBIO?

Do analysts recommend DMAC or JBIO?

Is DMAC or JBIO more profitable?

Which has more risk & volatility, DMAC or JBIO?

Does the media refer more to DMAC or JBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAC vs. The Competition

DiaMedica Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools